Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | FASN | P49327 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 6/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | F7 | P08709 | 1/20 | 0.35 |
| ▸ | F3 | P13726 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 3/20 | 0.33 |
| ▸ | CNR2 | P34972 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19973831 | 1.00 | TSHR (0.48) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL26905273 | 1.00 | TSHR (0.48) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL19974264 | 0.97 | TSHR (0.52) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL21484235 | 0.97 | TSHR (0.46) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL19974220 | 0.97 | TSHR (0.52) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL19974263 | 0.97 | TSHR (0.52) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL19974229 | 0.97 | TSHR (0.52) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL19974230 | 0.97 | TSHR (0.52) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL19974217 | 0.97 | TSHR (0.52) | TSHRALDH1A1FASNFAAHTRPV1 | |
| SCHEMBL18837279 | 0.95 | TSHR (0.45) | TSHRALDH1A1FASNFAAHTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12031130-B2 | Composition for modifying target gene | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-07-09 | — | — | US | disclosed |
| US-11993570-B2 | Cationic lipids | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-05-28 | — | — | US | disclosed |
| EP-3733641-B1 | CATIONIC LIPIDS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-04-10 | — | — | EP | disclosed |
| CN-111511713-B | Cationic lipid | 武田药品工业株式会社 | 2024-01-02 | — | — | CN | disclosed |
| CN-111527204-B | Composition for target gene modification | 国立大学法人京都大学 | 2023-09-01 | — | — | CN | disclosed |
| US-20230257338-A1 | CATIONIC LIPIDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20210371854-A1 | COMPOSITION FOR MODIFYING TARGET GENE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-12-02 | — | — | US | disclosed |
| EP-3733641-A1 | CATIONIC LIPIDS | Takeda Pharmaceutical Company Limited (JP) | 2020-11-04 | — | — | EP | disclosed |
| EP-3733844-A1 | COMPOSITION FOR MODIFYING TARGET GENE | Kyoto University (JP) | 2020-11-04 | — | — | EP | disclosed |
| US-20200331841-A1 | CATIONIC LIPIDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-22 | — | — | US | disclosed |
| WO-2018050794-A1 | PROCESS FOR PREPARING OF CAROTENOID MONO-ESTERS | BASF SE (DE) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018050795-A1 | PROCESS FOR PREPARING OF CAROTENOID MONO-ESTERS | BASF SE (DE) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018050793-A1 | PROCESS FOR PREPARING PHOSPHONIUM SALT ESTERS AS BUILDING BLOCKS FOR CAROTENOIDES | BASF SE (DE) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018050792-A1 | PROCESS FOR PREPARING ESTERS OF 12'-APOCAROTENALS AS BUILDING BLOCKS FOR CAROTENOIDS | BASF SE (DE) | 2018-03-22 | — | — | WO | disclosed |
| CN-1906183-B | N-acylsulfonamide apoptosis promoters | ABBOTT LAB | 2012-06-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11993570-B2 | Cationic lipids | ELOVL5, LPCAT3, ELOVL3 | TSHR 4055/4885ALDH1A1 3506/4885FASN 22/4885 |
| US-20210371854-A1 | COMPOSITION FOR MODIFYING TARGET GENE | NSUN2, NSUN3, RNASE1 | TSHR 3411/4885ALDH1A1 3452/4885FASN 36/4885 |
| US-12031130-B2 | Composition for modifying target gene | NSUN2, NSUN3, RNASE1 | TSHR 3411/4885ALDH1A1 3452/4885FASN 36/4885 |
| US-20230257338-A1 | CATIONIC LIPIDS | ELOVL5, LPCAT3, ELOVL3 | TSHR 4055/4885ALDH1A1 3506/4885FASN 22/4885 |
| US-20200331841-A1 | CATIONIC LIPIDS | ELOVL5, LPCAT3, ELOVL3 | TSHR 4055/4885ALDH1A1 3506/4885FASN 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.